Growth hormone stimulates the synthesis of RNA in hypophysectomized rat liver. The question whether the hormonal stimulation of RNA synthesis is due to the activation of repressed cistrons or to other factors was studied. Nuclear RNA from the livers of adult female hypophysectomized and growth-hormone-treated rats was examined for molecular homology by hybridization techniques: no new species of RNA were detected after hormone treatment. The template activity of the chromatin for RNA synthesis is also not increased by the action of growth hormone. Short- and long-pulse-labelling experiments demonstrate that the hormonal stimulation of RNA synthesis is most marked in experiments where the period of incorporation of radioactive precursors is limited to 1-2hr. It is concluded that the hormone influences essentially the rate of RNA synthesis in these tissues.

Animals↗

PubMed1964

Effect of growth hormone on ribonucleic acid metabolism. 3. Nature and characteristics of nuclear subfractions stimulated by hormone treatment.

Explore the source record for details and available documents.

Animals↗

PubMedDate not supplied

Congenital ocular abnormalities of the new born.

No information is available in the literature about the true incidence of congenital ocular abnormalities and associated systemic abnormalities in an Indian population. Initial results based on the first year of this study are presented. Out of 2,153 children born from January 1978 to December 1978, 2,016 were examined for any congenital ocular or systemic abnormality. The incidence of congenital ocular and systemic abnormalities was 10.5/1000 and 20/1000 live births respectively. Four out of 21 congenital ocular abnormalities were associated with congenital systemic abnormalities. Individual abnormalities are discussed in brief.

Abnormalities, Multiple↗

PubMedDate not supplied

Parenteral formulation development of renin inhibitor Abbott-72517.

Abbott-72517 is an inhibitor of human renin and is being investigated for the treatment of hypertension. It is an orally bioavailable candidate which is being developed for oral as well as intravenous use. The preclinical development of this molecule involved studies to evaluate irritation at the site of injection in an animal model. Several formulation variables such as drug concentration, types of buffer (citrate or acetate), addition of cosolvent (ethanol) to enhance drug solubility, and tonicity modifiers such as glycerin or mannitol were evaluated. Additionally, in vitro formulation--whole blood hemolysis and plasma precipitation studies were conducted. Based on these studies, a liquid formulation containing 1.2 mg/mL Abbott-72517.HCl as base, 0.01M citrate buffer, pH 3.7, in 0.45% sodium chloride containing 2.5% mannitol was recommended for preclinical studies. Various processing and administration parameters were evaluated including filter qualification and compatibility of the drug with typical infusion fluids and administration sets. The liquid formulation was further characterized for physical and chemical stability. It was shown that it has acceptable stability at ambient temperature. Based on the accelerated temperature storage results, T90 at 25 degrees C is > 1 year for the ready-to-use liquid formulation. Additionally, a lyophilized version of the liquid formulation was evaluated.

Animals↗